WO1998016246A1 - Cytokine enhanced immunotherapy for brain tumors - Google Patents

Cytokine enhanced immunotherapy for brain tumors Download PDF

Info

Publication number: WO1998016246A1
Authority: WO; WIPO (PCT)
Prior art keywords: cytokine; cells; mmor; tumor; csf
Prior art date: 1996-10-16

Application number

PCT/US1997/018455

Other languages

English (en)

French (fr)

Other versions

WO1998016246A9 (en

Inventor

Henry Brem

Drew M. Pardoll

Reid C. Thompson

Elizabeth M. Jaffee

Kam W. Leong

Matthew G. Ewend

Original Assignee

Johns Hopkins University

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-16

Filing date

1997-10-15

Publication date

1998-04-23

1997-10-15 Application filed by Johns Hopkins University filed Critical Johns Hopkins University

1997-10-15 Priority to CA002267977A priority Critical patent/CA2267977A1/en

1997-10-15 Priority to EP97910921A priority patent/EP0930892A1/de

1997-10-15 Priority to JP10518504A priority patent/JP2001502331A/ja

1997-10-15 Priority to AU48182/97A priority patent/AU4818297A/en

1998-04-23 Publication of WO1998016246A1 publication Critical patent/WO1998016246A1/en

1998-08-13 Publication of WO1998016246A9 publication Critical patent/WO1998016246A9/en

Links

102000004127 Cytokines Human genes 0.000 title claims abstract description 112
108090000695 Cytokines Proteins 0.000 title claims abstract description 112
208000003174 Brain Neoplasms Diseases 0.000 title abstract description 13
238000009169 immunotherapy Methods 0.000 title description 19
210000004027 cell Anatomy 0.000 claims abstract description 133
108010002350 Interleukin-2 Proteins 0.000 claims abstract description 117
206010028980 Neoplasm Diseases 0.000 claims abstract description 67
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims abstract description 58
238000011282 treatment Methods 0.000 claims abstract description 29
239000000427 antigen Substances 0.000 claims abstract description 21
102000036639 antigens Human genes 0.000 claims abstract description 21
108091007433 antigens Proteins 0.000 claims abstract description 21
108090000978 Interleukin-4 Proteins 0.000 claims abstract description 18
230000010076 replication Effects 0.000 claims abstract description 18
102000000588 Interleukin-2 Human genes 0.000 claims description 114
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 52
238000000034 method Methods 0.000 claims description 37
210000004556 brain Anatomy 0.000 claims description 32
239000000203 mixture Substances 0.000 claims description 30
238000009472 formulation Methods 0.000 claims description 22
230000003248 secreting effect Effects 0.000 claims description 19
102000004388 Interleukin-4 Human genes 0.000 claims description 16
229940028885 interleukin-4 Drugs 0.000 claims description 16
238000013270 controlled release Methods 0.000 claims description 10
239000011159 matrix material Substances 0.000 claims description 9
230000012010 growth Effects 0.000 claims description 8
239000011859 microparticle Substances 0.000 claims description 7
238000013268 sustained release Methods 0.000 claims description 6
239000012730 sustained-release form Substances 0.000 claims description 6
230000004614 tumor growth Effects 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 3
102000015696 Interleukins Human genes 0.000 claims 1
108010063738 Interleukins Proteins 0.000 claims 1
239000004005 microsphere Substances 0.000 abstract description 27
201000011510 cancer Diseases 0.000 abstract description 19
210000004881 tumor cell Anatomy 0.000 abstract description 19
238000002560 therapeutic procedure Methods 0.000 abstract description 17
239000003981 vehicle Substances 0.000 abstract description 7
238000007910 systemic administration Methods 0.000 abstract description 6
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract description 5
239000003937 drug carrier Substances 0.000 abstract description 4
241001465754 Metazoa Species 0.000 description 64
238000007917 intracranial administration Methods 0.000 description 60
230000004083 survival effect Effects 0.000 description 58
201000001441 melanoma Diseases 0.000 description 42
241000699670 Mus sp. Species 0.000 description 33
239000007924 injection Substances 0.000 description 31
238000002347 injection Methods 0.000 description 31
239000007943 implant Substances 0.000 description 30
238000012384 transportation and delivery Methods 0.000 description 27
238000002255 vaccination Methods 0.000 description 22
229920000642 polymer Polymers 0.000 description 21
230000009885 systemic effect Effects 0.000 description 18
239000002246 antineoplastic agent Substances 0.000 description 15
210000001744 T-lymphocyte Anatomy 0.000 description 14
239000002609 medium Substances 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
229940127089 cytotoxic agent Drugs 0.000 description 13
108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
230000000694 effects Effects 0.000 description 12
108090000623 proteins and genes Proteins 0.000 description 11
239000000126 substance Substances 0.000 description 11
229960005486 vaccine Drugs 0.000 description 11
230000000259 anti-tumor effect Effects 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
238000001727 in vivo Methods 0.000 description 10
238000012546 transfer Methods 0.000 description 10
238000001802 infusion Methods 0.000 description 9
210000003169 central nervous system Anatomy 0.000 description 8
238000000576 coating method Methods 0.000 description 8
230000028993 immune response Effects 0.000 description 8
230000007787 long-term memory Effects 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
108010074328 Interferon-gamma Proteins 0.000 description 7
229920002988 biodegradable polymer Polymers 0.000 description 7
239000004621 biodegradable polymer Substances 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
231100000419 toxicity Toxicity 0.000 description 7
230000001988 toxicity Effects 0.000 description 7
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
208000001382 Experimental Melanoma Diseases 0.000 description 6
102100039064 Interleukin-3 Human genes 0.000 description 6
102000004889 Interleukin-6 Human genes 0.000 description 6
108090001005 Interleukin-6 Proteins 0.000 description 6
230000006023 anti-tumor response Effects 0.000 description 6
229960004562 carboplatin Drugs 0.000 description 6
190000008236 carboplatin Chemical compound 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
238000002648 combination therapy Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
229940079593 drug Drugs 0.000 description 6
229940100601 interleukin-6 Drugs 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
230000007774 longterm Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000007929 subcutaneous injection Substances 0.000 description 6
238000010254 subcutaneous injection Methods 0.000 description 6
238000011740 C57BL/6 mouse Methods 0.000 description 5
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
102100037850 Interferon gamma Human genes 0.000 description 5
108010002386 Interleukin-3 Proteins 0.000 description 5
102000000704 Interleukin-7 Human genes 0.000 description 5
108010002586 Interleukin-7 Proteins 0.000 description 5
206010027476 Metastases Diseases 0.000 description 5
241001529936 Murinae Species 0.000 description 5
238000009792 diffusion process Methods 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
239000000945 filler Substances 0.000 description 5
230000006870 function Effects 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
238000011221 initial treatment Methods 0.000 description 5
229940076264 interleukin-3 Drugs 0.000 description 5
229940100994 interleukin-7 Drugs 0.000 description 5
210000002864 mononuclear phagocyte Anatomy 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000005563 spheronization Methods 0.000 description 5
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
206010018338 Glioma Diseases 0.000 description 4
210000003719 b-lymphocyte Anatomy 0.000 description 4
239000011230 binding agent Substances 0.000 description 4
230000008499 blood brain barrier function Effects 0.000 description 4
210000001218 blood-brain barrier Anatomy 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
230000034994 death Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000002962 histologic effect Effects 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
210000000822 natural killer cell Anatomy 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
229920001059 synthetic polymer Polymers 0.000 description 4
239000013598 vector Substances 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
208000032612 Glial tumor Diseases 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
229920002732 Polyanhydride Polymers 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000004913 activation Effects 0.000 description 3
230000005975 antitumor immune response Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
229920006008 lipopolysaccharide Polymers 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
210000001152 parietal lobe Anatomy 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000003362 replicative effect Effects 0.000 description 3
238000002271 resection Methods 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
238000011521 systemic chemotherapy Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
GDFUWFOCYZZGQU-UHFFFAOYSA-N 4-propoxybenzoic acid Chemical compound CCCOC1=CC=C(C(O)=O)C=C1 GDFUWFOCYZZGQU-UHFFFAOYSA-N 0.000 description 2
206010048962 Brain oedema Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
206010059282 Metastases to central nervous system Diseases 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
208000006752 brain edema Diseases 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000009505 enteric coating Methods 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
239000005038 ethylene vinyl acetate Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
229940044627 gamma-interferon Drugs 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
210000003630 histaminocyte Anatomy 0.000 description 2
238000010231 histologic analysis Methods 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000009401 metastasis Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000001936 parietal effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920002627 poly(phosphazenes) Polymers 0.000 description 2
239000004633 polyglycolic acid Substances 0.000 description 2
229950008885 polyglycolic acid Drugs 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000009781 safety test method Methods 0.000 description 2
238000000807 solvent casting Methods 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000041 toxicology testing Toxicity 0.000 description 2
210000003556 vascular endothelial cell Anatomy 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
UYKWDAPDQOLFRV-UHFFFAOYSA-N 2-methyloxirane;molecular iodine;oxirane Chemical compound II.C1CO1.CC1CO1 UYKWDAPDQOLFRV-UHFFFAOYSA-N 0.000 description 1
LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
108020000946 Bacterial DNA Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
208000014061 Extranodal Extension Diseases 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
206010019695 Hepatic neoplasm Diseases 0.000 description 1
101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920001273 Polyhydroxy acid Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101150033527 TNF gene Proteins 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
229920002494 Zein Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001772 anti-angiogenic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
229940121357 antivirals Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004271 bone marrow stromal cell Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
150000004648 butanoic acid derivatives Chemical class 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
238000009566 cancer vaccine Methods 0.000 description 1
229940022399 cancer vaccine Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
229940030156 cell vaccine Drugs 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011220 combination immunotherapy Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000007599 discharging Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
239000000806 elastomer Substances 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
239000002095 exotoxin Substances 0.000 description 1
231100000776 exotoxin Toxicity 0.000 description 1
238000002710 external beam radiation therapy Methods 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000001652 frontal lobe Anatomy 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000036039 immunity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000011293 immunotherapeutic strategy Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
210000000274 microglia Anatomy 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
229940045057 prepodyne Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000002330 subarachnoid space Anatomy 0.000 description 1
239000003356 suture material Substances 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
231100000057 systemic toxicity Toxicity 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001005 tuberculin Drugs 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
230000005760 tumorsuppression Effects 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000035899 viability Effects 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
239000005019 zein Substances 0.000 description 1
229940093612 zein Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

cytokines including IL-3 and IL-7 can be secreted from cells by applying the methods used for the cytokines described above or by the general procedures for genetically modifying nonimmunogenic murine fibrosarcoma described in Karp, S. E. , et al., /. Immunol. , 150:896-908 (1993) and Jaffee, E. et al., J. Immunotherapy, in press (1995).
the publications cited above describe methods of genetically engineering cells to secrete cytokines.
cancer vaccines expressing two or more cytokines from engineered vectors containing genes encoding two different cytokines or by sequential recombinant retrovirus-mediated genetic transductions can be prepared.
Example 4 Intracranial delivery of microencapsulated interleukin-2 produces long term memory and protects against re- challenges

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PCT/US1997/018455 1996-10-16 1997-10-15 Cytokine enhanced immunotherapy for brain tumors WO1998016246A1 (en)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
CA002267977A CA2267977A1 (en)	1996-10-16	1997-10-15	Cytokine enhanced immunotherapy for brain tumors
EP97910921A EP0930892A1 (de)	1996-10-16	1997-10-15	Zytokin-erhoehte immuntherapie gegen gehirntumore
JP10518504A JP2001502331A (ja)	1996-10-16	1997-10-15	脳腫瘍に対するサイトカインで増強した免疫療法
AU48182/97A AU4818297A (en)	1996-10-16	1997-10-15	Cytokine enhanced immunotherapy for brain tumors

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73159796A	1996-10-16	1996-10-16
US08/731,597		1996-10-16

Publications (2)

Publication Number	Publication Date
WO1998016246A1 true WO1998016246A1 (en)	1998-04-23
WO1998016246A9 WO1998016246A9 (en)	1998-08-13

Family

ID=24940192

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/US1997/018455 WO1998016246A1 (en)	1996-10-16	1997-10-15	Cytokine enhanced immunotherapy for brain tumors

Country Status (5)

Country	Link
EP (1)	EP0930892A1 (de)
JP (1)	JP2001502331A (de)
AU (1)	AU4818297A (de)
CA (1)	CA2267977A1 (de)
WO (1)	WO1998016246A1 (de)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076564A1 (de) *	1998-04-02	2001-02-21	The Regents of the University of California	Verfahren zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
US6193970B1 (en) *	1993-12-14	2001-02-27	The Johns Hopkins University School Of Medicine	Controlled release of pharmaceutically active substances for immunotherapy
WO2001047546A2 (en) *	1999-12-28	2001-07-05	Brown University Research Foundation	Methods and products for tumor immunotherapy using cytokines
US6277368B1 (en)	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
WO2003080111A2 (en) *	2002-03-25	2003-10-02	Technologies Biolactis Inc.	Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
JP2004501981A (ja) *	2000-06-29	2004-01-22	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US6911204B2 (en)	2000-08-11	2005-06-28	Favrille, Inc.	Method and composition for altering a B cell mediated pathology
WO2006008582A1 (en) *	2004-06-30	2006-01-26	Sygnis Bioscience Gmbh / Co. Kg	Treatment of neurological disorders with hematopoeitic growth factors
US9814682B2 (en)	2002-06-17	2017-11-14	Maxivax Sa	Vaccination with immuno-isolated cells producing an immunomodulator
US9861689B2 (en)	2015-09-25	2018-01-09	Maxivax Sa	Vaccination with immuno-isolated cells producing an immunomodulator

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220403001A1 (en)	2018-06-12	2022-12-22	Obsidian Therapeutics, Inc.	Pde5 derived regulatory constructs and methods of use in immunotherapy
US20220056092A1 (en)	2018-12-11	2022-02-24	Obsidian Therapeutics, Inc.	Membrane bound il12 compositions and methods for tunable regulation
CA3132840A1 (en)	2019-03-08	2020-09-17	Obsidian Therapeutics, Inc.	Human carbonic anhydrase 2 compositions and methods for tunable regulation
AU2020290522A1 (en)	2019-06-12	2022-01-20	Obsidian Therapeutics, Inc.	CA2 compositions and methods for tunable regulation
US20220267398A1 (en)	2019-06-12	2022-08-25	Obsidian Therapeutics, Inc.	Ca2 compositions and methods for tunable regulation
WO2021040736A1 (en)	2019-08-30	2021-03-04	Obsidian Therapeutics, Inc.	Tandem cd19 car-based compositions and methods for immunotherapy
MX2022002747A (es)	2019-09-10	2022-04-06	Obsidian Therapeutics Inc	Proteinas de fusion de ca2-il15 para regulacion ajustable.

1997
- 1997-10-15 JP JP10518504A patent/JP2001502331A/ja active Pending
- 1997-10-15 AU AU48182/97A patent/AU4818297A/en not_active Abandoned
- 1997-10-15 CA CA002267977A patent/CA2267977A1/en not_active Abandoned
- 1997-10-15 WO PCT/US1997/018455 patent/WO1998016246A1/en not_active Application Discontinuation
- 1997-10-15 EP EP97910921A patent/EP0930892A1/de not_active Ceased

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BELLDEGRUN ET AL: "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, 1993, pages 207 - 216, XP002057839 *
DRANOFF ET AL: "VACCINATION WITH IRRADIATED TUMOR CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTI-TUMOR IMMUNITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, vol. 90, 1993, pages 3539 - 3543, XP002057840 *
GOLUMBEK ET AL: "CONTROLLED RELEASE, BIODEGRADABLE CYTOKINE DEPOTS: A NEW APPROACH IN CANCER VACCINE DESIGN", CANCER RESEARCH, vol. 53, 1993, pages 5841 - 5844, XP002057841 *
HOLLINGSWORTH ET AL: "THE EFFECT OF COMBINED EXPRESSSION OF INTERLEUKIN 2 AND INTERLEUKIN 4 ON THE TUMORIGENICITY AND TREATMENT OF B16F10 MELANOMA", BRITISH JOURNAL OF CANCER, vol. 74, July 1996 (1996-07-01), pages 6 - 15, XP002057838 *
PAPPO ET AL: "ADMINISTRATION OF SYSTEMIC OR LOCAL INTERLEUKIN-2 ENHANCES THE ANTI-TUMOR EFFECTS OF INTERLEUKIN-12 GENE THERAPY", JOURNAL OF SURGICAL RESEARCH, vol. 58, 1995, pages 218 - 226, XP002057836 *
PIPPIN ET AL: "LOCAL IL-4 DELIVERY ENHANCES IMMUNE REACTIVITY TO MURINE TUMORS: GENE THERAPY IN COMBINATION WITH IL2", CANCER GENE THERAPY, vol. 1, no. 1, 1994, pages 35 - 42, XP002057835 *
THOMPSON ET AL: "SYSTEMIC AND LOCAL PARACRINE CYTOKINE THERAPIES USING TRANSDUCED TUMOR CELLS ARE SYNERGISTIC IN TREATING INTRACRANIAL TUMORS", JOURNAL OF IMMUNOTHERAPY, vol. 19, no. 6, November 1996 (1996-11-01), pages 405 - 413, XP002057842 *
VAGLIANI ET AL: "INTERLEUKIN 12 POTENTIATES THE CURATIVE EFFECT OF A VACCINE BASED ON INTERLEUKIN 2-TRANSDUCED TUMOR CELLS", CANCER RESEARCH, vol. 56, 1 February 1996 (1996-02-01), pages 467 - 470, XP002057837 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6193970B1 (en) *	1993-12-14	2001-02-27	The Johns Hopkins University School Of Medicine	Controlled release of pharmaceutically active substances for immunotherapy
US7264820B2 (en)	1996-07-25	2007-09-04	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline
US7364726B2 (en)	1996-07-25	2008-04-29	The Regents Of The University Of California	Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine
US6277368B1 (en)	1996-07-25	2001-08-21	The Regents Of The University Of California	Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
EP1076564A4 (de) *	1998-04-02	2005-02-23	Univ California	Verfahren zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
EP1076564A1 (de) *	1998-04-02	2001-02-21	The Regents of the University of California	Verfahren zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
WO2001047546A3 (en) *	1999-12-28	2001-12-06	Univ Brown Res Found	Methods and products for tumor immunotherapy using cytokines
WO2001047546A2 (en) *	1999-12-28	2001-07-05	Brown University Research Foundation	Methods and products for tumor immunotherapy using cytokines
JP2004501981A (ja) *	2000-06-29	2004-01-22	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	免疫サイトカインの取り込み増強剤との併用治療による抗体−サイトカイン融合タンパク質媒介免疫応答の増強
US6911204B2 (en)	2000-08-11	2005-06-28	Favrille, Inc.	Method and composition for altering a B cell mediated pathology
US8114404B2 (en)	2000-08-11	2012-02-14	Mmrglobal, Inc.	Method and composition for altering a B cell mediated pathology
US8133486B2 (en)	2000-08-11	2012-03-13	Mmrglobal, Inc.	Method and composition for altering a B cell mediated pathology
US8637638B2 (en)	2000-08-11	2014-01-28	Mmrglobal, Inc.	Method and composition for altering a B cell mediated pathology
WO2003080111A3 (en) *	2002-03-25	2003-11-13	Technologies Biolactis Inc	Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
WO2003080111A2 (en) *	2002-03-25	2003-10-02	Technologies Biolactis Inc.	Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof
US9814682B2 (en)	2002-06-17	2017-11-14	Maxivax Sa	Vaccination with immuno-isolated cells producing an immunomodulator
WO2006008582A1 (en) *	2004-06-30	2006-01-26	Sygnis Bioscience Gmbh / Co. Kg	Treatment of neurological disorders with hematopoeitic growth factors
US9861689B2 (en)	2015-09-25	2018-01-09	Maxivax Sa	Vaccination with immuno-isolated cells producing an immunomodulator
US11013790B2 (en)	2015-09-25	2021-05-25	Maxivax Sa	Vaccination with immuno-isolated cells producing an immunomodulator

Also Published As

Publication number	Publication date
AU4818297A (en)	1998-05-11
JP2001502331A (ja)	2001-02-20
CA2267977A1 (en)	1998-04-23
EP0930892A1 (de)	1999-07-28

Legal Events

Date	Code	Title	Description
1998-04-23	AK	Designated states	Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM
1998-04-23	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
1998-07-09	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
1998-08-13	COP	Corrected version of pamphlet	Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE
1998-08-26	121	Ep: the epo has been informed by wipo that ep was designated in this application
1998-09-24	CFP	Corrected version of a pamphlet front page	Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE
1999-04-07	ENP	Entry into the national phase	Ref document number: 2267977 Country of ref document: CA Ref country code: CA Ref document number: 2267977 Kind code of ref document: A Format of ref document f/p: F
1999-04-15	ENP	Entry into the national phase	Ref country code: JP Ref document number: 1998 518504 Kind code of ref document: A Format of ref document f/p: F
1999-05-18	WWE	Wipo information: entry into national phase	Ref document number: 1997910921 Country of ref document: EP
1999-07-16	WWE	Wipo information: entry into national phase	Ref document number: 09284547 Country of ref document: US
1999-07-28	WWP	Wipo information: published in national office	Ref document number: 1997910921 Country of ref document: EP
2002-03-24	WWR	Wipo information: refused in national office	Ref document number: 1997910921 Country of ref document: EP
2002-07-04	WWW	Wipo information: withdrawn in national office	Ref document number: 1997910921 Country of ref document: EP

Publication	Publication Date	Title
Hanes et al.	2001	Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors
Riley et al.	2019	Delivery technologies for cancer immunotherapy
Yang et al.	2020	Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy
EP0930892A1 (de)	1999-07-28	Zytokin-erhoehte immuntherapie gegen gehirntumore
WO1998016246A9 (en)	1998-08-13	Cytokine enhanced immunotherapy for brain tumors
CA2194555C (en)	2002-01-29	Implanted device containing tumor cells for the treatment of cancer
Egilmez et al.	2000	In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity
US5861159A (en)	1999-01-19	Controlled release of pharmaceutically active substances for immunotherapy
US6156305A (en)	2000-12-05	Implanted tumor cells for the prevention and treatment of cancer
EP0774964B1 (de)	2005-03-16	Kontrollierte, lokale verabreichung von chemotherapeutischen wirkstoffen zur behandlung von festen tumoren
US4832686A (en)	1989-05-23	Method for administering interleukin-2
Xie et al.	2018	Immunoengineering with biomaterials for enhanced cancer immunotherapy
US9814682B2 (en)	2017-11-14	Vaccination with immuno-isolated cells producing an immunomodulator
EP2421505A2 (de)	2012-02-29	Hydrogele für die kombinatorische freisetzung von immunmodulierenden biomolekülen
JP2024050581A (ja)	2024-04-10	腫瘍の増殖及び転移を阻害するためのコルヒチンの使用
Wang et al.	2022	Construction of single-injection vaccine using new time-controlled release system
Egilmez et al.	2007	Controlled-release particulate cytokine adjuvants for cancer therapy
US20040005302A1 (en)	2004-01-08	Encapsulated cells to elicit immune responses
EP1143934A1 (de)	2001-10-17	Genetische immunisierung mit gleichzeitiger verabreichung von nukleinsäuren und zytokinen
Amsden	2007	Review of osmotic pressure driven release of proteins from monolithic devices
WO2020038298A1 (zh)	2020-02-27	一种基于微囊的疫苗
Stokes Jr	2021	Immunomodulatory biomaterials for cancer immunotherapy
TW442294B (en)	2001-06-23	Device and process for manufacturing a device for implanting tumor cells for the prevention and treatment of cancer
Zhang et al.	2024	Macrophage membrane-coated Eucommia ulmoides polysaccharides-loaded PLGA nanoparticles as an effective antigen-targeted delivery system
JP2001199879A (ja)	2001-07-24	薬物放出製剤